The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
RTOG 3506 (STEEL): A study of salvage radiotherapy with or without enzalutamide in recurrent prostate cancer following surgery.
 
Edwin Melencio Posadas
Consulting or Advisory Role - CytoLumina; Genentech/Roche; Janssen Oncology; Janssen Oncology; Novartis
Speakers' Bureau - Bayer
Research Funding - PFizer
Patents, Royalties, Other Intellectual Property - Patent on NanoVelcro Assay for CTCs in prostate cancer
Travel, Accommodations, Expenses - TRACON Pharma
 
Hiram Alberto Gay
No Relationships to Disclose
 
Stephanie L. Pugh
No Relationships to Disclose
 
Todd Matthew Morgan
Consulting or Advisory Role - Myriad Genetics; TERUMO
Research Funding - GenomeDx (Inst); MDxHealth (Inst); Myriad Genetics (Inst)
 
James B. Yu
Honoraria - Boston Scientific
Consulting or Advisory Role - Boston Scientific; Galera Therapeutics
 
Stanislav Lechpammer
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Felix Y Feng
Leadership - PFS Genomics
Stock and Other Ownership Interests - Nutcracker Therapeutics, Inc.; PFS Genomics; SerImmune
Honoraria - Genentech
Consulting or Advisory Role - Bayer; Blue Earth Diagnostics; Celgene; EMD Serono; Genzyme; Janssen Biotech; Medivation/Astellas
Research Funding - Zenith Epigenetics
Patents, Royalties, Other Intellectual Property - I helped develop a molecular signature to predict radiation resistance in breast cancer, and this signature was patented by the University of Michigan, my employer. It is in the process of being licensed to PFS Genomics, a company that I helped found. (Inst)